BiotechTube

Trastuzumab + Fluorouracil + Cisplatin + Capecitabine

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer

Trial Timeline

Sep 1, 2005 → Jun 1, 2010

NCT ID
NCT01041404

About Trastuzumab + Fluorouracil + Cisplatin + Capecitabine

Trastuzumab + Fluorouracil + Cisplatin + Capecitabine is a phase 3 stage product being developed by Chugai Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01041404. Target conditions include Gastric Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01041404Phase 3Completed

Competing Products

20 competing products in Gastric Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77